What has FDA cited under NAFDAC 5+5 Policy?

1 DSRV article cite NAFDAC 5+5 Policy. Enforcement cases behind them: NAFDAC 5+5 Policy results published March 2026: 191 applications, 185 approved, 108 facility layouts cleared, 20 completed, 88 under construction. 58% first-time manufacturers. Inspection exposure across them: 1 high.

What does DSRV recommend for NAFDAC 5+5 Policy?

From the newest article (108 New Drug Facilities in Nigeria. Most Have Never Been Inspected.): NAFDAC approval confirms a facility was built. It does not confirm the quality system inside it is ready for WHO-PQ or FDA scrutiny. The 63 first-time manufacturers entering Nigeria's supply chain carry inspection risk proportional to their lack of prior GMP testing. DSRV is decision support, not legal advice; verify against the official source each article names.

Browse by regulation1 article · 1 high

NAFDAC 5+5 Policy

Every DSRV article whose Regulatory Snapshot cites NAFDAC 5+5 Policy: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set

What has FDA cited under NAFDAC 5+5 Policy?: 1 DSRV article cite NAFDAC 5+5 Policy. Enforcement cases behind them: NAFDAC 5+5 Policy results published March 2026: 191 applications, 185 approved, 108 facility layouts cleared, 20 completed, 88 under construction. 58% first-time manufacturers. Inspection exposure across them: 1 high.
What does DSRV recommend for NAFDAC 5+5 Policy?: From the newest article (108 New Drug Facilities in Nigeria. Most Have Never Been Inspected.): NAFDAC approval confirms a facility was built. It does not confirm the quality system inside it is ready for WHO-PQ or FDA scrutiny. The 63 first-time manufacturers entering Nigeria's supply chain carry inspection risk proportional to their lack of prior GMP testing. DSRV is decision support, not legal advice; verify against the official source each article names.

June 20266 min readHigh exposurecited as a tag
108 New Drug Facilities in Nigeria. Most Have Never Been Inspected.
NAFDAC's 5+5 Policy approved 108 new pharmaceutical manufacturing sites by early 2026. Sixty-three of them are first-time manufacturers with no inspection history, entering a supply chain where WHO prequalification assessments will test what local approval did not.
Case
NAFDAC 5+5 Policy results published March 2026: 191 applications, 185 approved, 108 facility layouts cleared, 20 completed, 88 under construction. 58% first-time manufacturers.
DSRV take
NAFDAC approval confirms a facility was built. It does not confirm the quality system inside it is ready for WHO-PQ or FDA scrutiny. The 63 first-time manufacturers entering Nigeria's supply chain carry inspection risk proportional to their lack of prior GMP testing.

Address this risk

Pressure-test your evidence before an inspector reads it

Bring the document that has to hold up under NAFDAC 5+5 Policy. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about NAFDAC 5+5 Policy

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.